Seeking Alpha

Watson Pharmaceuticals (WPI) receives final FDA approval for its lidocaine topical patch 5%, the...

Watson Pharmaceuticals (WPI) receives final FDA approval for its lidocaine topical patch 5%, the generic equivalent to Endo Health Solutions's (ENDP) Lidoderm. The drug developer plans to launch the product in September, pursuant with its settlement agreement with ENDP and believes that under Hatch Waxman rules, it will be entitled to 180 days of marketing exclusivity. WPI +0.2%, ENDP -3.7% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector